Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma From 2015 to May 2021, 22,886 patients were ...
Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT* phase 3 study experience. Background: Pazopanib is an oral, selective, multikinase inhibitor of VEGF receptors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results